PCSK9 and myocardial infarction: In the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial, patients received either evolocumab or placebo, and evolocumab reduced the risk of CV events such as CV death, myocardial infarction, stroke, or coronary revascularization, but there was no difference in mortality.